CureGene Doses First Patient in Pivotal Evategrel Trial
SHANGHAI, China, June 22, 2026 CureGene Pharmaceutical has announced the successful dosing of the first participant in the U.S....
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, China, June 22, 2026 CureGene Pharmaceutical has announced the successful dosing of the first participant in the U.S....
BOSTON, Singapore and Hong Kong, June 22, 2026 Antengene Corporation Limited has announced a landmark strategic licensing agreement with...
